Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: The P.I.C.X.E.L. Study rationale and design

Journal of Human Hypertension

Volumn 16, Issue 9, 2002, Pages 653-659

  Gosse, Philippe ^a   Dubourg, O ^b   Gueret P ^c   De Simone, G ^d   Schmieder, R ^e   De Leeuw, P W ^f   Degaute, J P ^g   Garcia Puig, J ^h   Karpov, Y ⁱ   Magometschnigg, D ^j   Matos, L ^k   Amouyel, P ^l   Asmar, R ^m   Le Heuzey, J Y ⁿ   Nieminen, M ^o   Dahlof B ^p  

^a HÔPITAL SAINT ANDRÉ   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Medizinische Klinik IV   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ERASME HOSPITAL   (Belgium)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^j Institut fur Hypertoniker Vienna   (Austria)

^k Hungarian Institute of Cardiology   (Hungary)

^l INSTITUT PASTEUR DE LILLE   (France)

^m Institut Cardiovasculaire   (France)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^p UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

Centralised assessment; Hypertension; Left ventricular hypertrophy; Very low dose combination ACE inhibitor diuretic combination

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; PERINDOPRIL; PLACEBO;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFORMATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; LABORATORY TEST; LONG TERM CARE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; OUTPATIENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STUDENT T TEST;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INDAPAMIDE; MALE; PERINDOPRIL; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0036745537     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001467     Document Type: Article

References (45)

1. Levy D et al. Prognostic implication of echocardiographically-determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Ghali JK et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-836.
3. Bikkina M et al. Left ventricular mass and the risk of stroke in an elderly cohort. JAMA 1994; 272: 33-36.
4. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
5. Casale PN, Devereux RB, Milner M. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
6. Verdecchia P et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
7. Cipriano C et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14: 524-529.
8. CPMP 1994, 1997: Committee for proprietary medicinal products. Note for guidance on clinical investigation of medicinal products in the treatment of hypertension. CPMP/EWP/238/95/1997.
9. Devereux RB et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996; 14: S95-S102.
10. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95: 1983-1985.
11. Lavie CJ, Ventura HO, Messerli FH. Regression of increased left ventricular mass by antihypertensives. Drugs 1991; 42: 945-961.
12. Gottdiener JS et al. Effect of single drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. The Department of Veterans Affairs Co-operative study group on antihypertensives. Circulation 1997; 95: 2007-2014.
13. Jennings G, Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analyses. J Hypertens 1998; 16: S29-S34.
14. Schmeider RE, Martus P, Klingbeil AU. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomised double-blind studies. JAMA 1996; 275: 1507-1513.
15. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension. (A meta-analysis of all randomised double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-569.
16. Dahlöf B, Pennert K, Hannson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
17. Cruickshank J, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85-90.
18. Gosse P et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: The LIVE study. J Hypertens 2000; 18: 1465-1475.
19. Asmar GM, London ME, O'Rourke ME, Safar M. Improvement in blood pressure and arterial stiffness with a very-low-dose Perindopril/Indapamide combination in hypertensive patients. A comparison with atenolol. Hypertension 2001; 38: 922-926.
20. Chanudet X, de Champavallins MC. Antihypertensive efficacy and tolerability of the low-dose perindopril-indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Practice 2001; 55: 233-239.
21. Morgan T, Anderson A, Lauri J. Low-dose combination therapy (Perindopril, Indapamide) compared with irbesartan monotherapy. J Hypertens 2001; 9 (Suppl 2): S235.
22. Safar M et al. Perindopril and indapamide as a combination in the treatment of mild to moderate hypertension. Am J Hypertens 1994; 7: 43A.
23. Myers M, Asmar R, Leenen F, Safar M. Fixed low-dose combination therapy in hypertension. A dose response study of perindopril and indapamide. J Hypertens 2000; 18: 317-325.
24. Meyrier A, Dratwa M, Sennesael J. Lachaud-Pettiti V. Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Am J Hypertens 1998; 11: 1087-1092.
25. Forette B. Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives. J Hum Hypertens 1999; 13: 211-213.
26. Matheson AJ, Cheer SM, Goa KL. Perindopril/Indapamide 2/0.625 mg/day a review of its place in the management of hypertension. Drugs 2001; 61: 1211-1229.
27. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed very low-dose ACE-inhibitor/diuretic combination as first line therapy in elderly hypertensive patients. J Hypertens 2000; 18: 327-337.
28. Levy BI et al. Effect of low doses of perindopril and indapamide alone or in combination (Preterax) in renovascular hypertensive rats. Eur Heart J 1999; 1 (Suppl L): L50-L57.
29. Richard V, Thuillez C. Improvement of endothelial function with the fixed low-dose perindopril-indapamide combination. Eur Heart J 1999; 1 (Suppl L): L39-L43.
30. Rakusan K et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 2000; 59: 243-254.
31. Levy B, Duriez M, Samuel JL. Coronary microvasculature density in hypertensive rats. Alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens 2001; 14: 7-13.
32. De Luca N, Safar M, on behalf of the international coordination group. Efficacy of a very low-dose perindopril 2mg/indapamide 0.625mg on cardiac hypertrophy in hypertensive patients. the REASON project. J Hypertens 2002; 20 (Suppl 4): S164.
33. Mansoor GA, Massie BM. Left ventricular hypertrophy: a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure. Blood Press Monit 1999; 4: S19-S22.
34. Herpin D et al. Heart rate and blood pressure variabilities in mild to moderate hypertensive patients with or without left ventricular hypertrophy. Archives des maladies du coeur et des vaisseaux 1996; 89: 1059-1063.
35. Palmiero P, Maiello M. Ventricular arrythmias and left ventricular hypertrophy in essential hypertension. Minerva Cardioangiol 2000; 48: 427-434.
36. Oikarinen L et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients; The LIFE study. J Hypertens 2001; 19: 1883-1891.
37. Devereux RB, Reichek N. Echocardiographic determination of LVM in man: anatomic validation of the method. Circulation 1977; 5: 613-618.
38. Devereux RB et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
39. De Simone G et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
40. Gosse P et al. Measures semi automatiques de la masse ventriculaire gauche œ partir des traces TM du ventricule gauche. Arch Mal Cœur 1999; 92: 961-963.
41. Reid JL. Pharmacokinetic and pharmacodynamic aspects of the choice of components of combination therapy. J Hum Hypertens 1995; 9 (Suppl 4): S19-S23.
42. Devereux RB, Dahlof B. Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-739.
43. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 1995; 25: 424-430.
44. Gosse P et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 531-535.
45. Bottini PB et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8: 221-228.